The latest update is out from Aurora Spine ( (TSE:ASG) ).
Aurora Spine Corporation has completed patient enrollment for its REFINE study, which is the first prospective, multi-center, multi-specialty trial to evaluate the safety and efficacy of lumbar interlaminar fusion devices. This study aims to provide robust, long-term insights into patient outcomes and is expected to influence future clinical decision-making and elevate the standard of care in spinal fusion. The results will be presented at the ASPN annual conference in July 2025, highlighting Aurora Spine’s commitment to evidence-based innovation and offering a less invasive alternative to traditional spinal surgery.
More about Aurora Spine
Aurora Spine Corporation is a designer and manufacturer of innovative medical devices aimed at improving spinal surgery outcomes. The company focuses on providing solutions for spinal care, specifically targeting conditions like lumbar spinal stenosis and degenerative disc disease with minimally invasive technologies.
YTD Price Performance: -19.25%
Average Trading Volume: 45,141
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: C$24.94M
See more insights into ASG stock on TipRanks’ Stock Analysis page.